Alpaslan KABAN

Dr. Alpaslan KABAN


Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 March 2018 in Journal of Obstetrics and Gynaecology Research
Verified
Journal Article
Closed access
PDF file
IKışık Kaban
ışık Kaban
AKAlpaslan KABAN
Alpaslan KABAN
ATAysun F. Tunca
Aysun F. Tunca
NANurettin Aka
Nurettin Aka
HKHacer Kavak
Hacer Kavak
FAFugen Akar
Fugen Akar

1 May 2017 in Gynecologic Oncology Reports
Verified
Journal Article
Open access
AKAlpaslan KABAN
Alpaslan KABAN
IKIşık Kaban
Işık Kaban
Selim AfsarSelim Afsar
Selim Afsar
Vulvar cancers, which constitute 5% of all gynecologic cancers, are the fourth most common female genital cancers, preceded by uterine, ovarian and cervical cancers. The treatment methods employed for vulvar cancers have changed over the years, with previously applied radical surgical approaches, such as en bloc resection, being gradually suspended in favor of treatment approaches that require dissection of less tissue. While the removal of less tissue, which today's approaches have focused on, prevents morbidity, this method seems to result in higher risks of recurrence. It is therefore important that the balance between preventing the recurrence of the disease and forefending against postoperative complications and vulvar deformity be properly understood. As a working assumption, if patients with vulvar cancer are diagnosed at an early stage, properly evaluated and administered appropriate treatment, the most positive results can be obtained. This paper aims to highlight this assumption and demonstrate, through the provision of actual data, how to plan the treatment approach for patients who are diagnosed early. Statements extracted from the National Comprehensive Cancer Network (NCCN) Guidelines Version 1.2016 Sub-Committees on vulvar squamous cell carcinoma and articles by the European Society of Gynaecological Oncology (ESGO) regarding Vulvar Cancer Recommendations were used to obtain updated information.

1 December 2017 in Journal of Obstetrics and Gynaecology Canada
Verified
Journal Article
Closed access
AKAlpaslan KABAN
Alpaslan KABAN
STSamet Topuz
Samet Topuz
PSPinar Saip
Pinar Saip
HSHamdullah Sozen
Hamdullah Sozen
KCKoray Celebi
Koray Celebi
YSYavuz Salihoglu
Yavuz Salihoglu

1 March 2018 in Journal of the Turkish-German Gynecological Association
Verified
Journal Article
Open access
AKAlpaslan KABAN
Alpaslan KABAN
STSamet Topuz
Samet Topuz
HSHamdullah Sözen
Hamdullah Sözen
YMYağmur Minareci
Yağmur Minareci
YSYavuz Salihoğlu
Yavuz Salihoğlu
To review the clinicopathologic and survival outcomes of patients with serous endometrial cancer (EC) and to investigate subgroup analysis based on pure serous and mixed serous EC subtypes. Patients who underwent EC surgery between 2002 and 2014 and who were reported as serous EC were enrolled in the study. All patients were diagnosed as having serous EC or mixed serous EC with serous component higher than 10% based on the postoperative pathology report. A total of 93 patients were analyzed. The median disease-free and overall survival (OS) durations were 49.6 and 32.2 months, respectively. Forty-three patients (46.2%) relapsed and 35 patients (37.6%) died. The histologic type was pure serous EC in 52 (55.9%) and mixed EC in 41 (44.9%) patients. There was no statistical difference between the pure serous and mixed serous groups in terms of age, International Federation of Gynecology and Obstetrics stage, lymphadenectomy, lymph node metastasis or adjuvant therapy combinations. Twenty-nine (55.8%) patients in the pure serous group and 14 (34.1%) in the mixed serous group hade recurrence (p=0.038). Twenty-five (48.1%) patients in the pure serous group and 10 (24.4%) in the mixed serous group died (p=0.034). In the pure serous group, the mean disease-free and OS durations were shorter than in the mixed serous group (59 vs. 81 months and 73 vs. 95 months, log-rank p=0.055 and 0.041, respectively). Histologic type was a significant prognostic factor on recurrence and OS in the univariate analysis (Hazard ratio: 2.404, 95% Confidence interval: 1.01-5.71; 2.027, respectively), but not in the multivariate analysis, which included disease stage and age of the patients. Compared with pure serous and mixed serous endometrium cancer groups, primary surgical treatments, clinicopathologic features and adjuvant treatments were similar, but there was a survival difference. Patients with pure serous cancer had a worse prognosis. However histology was not an independent factor for survival.

1 April 2018 in Journal of Obstetrics and Gynaecology Canada
Verified
Journal Article
Closed access
AKAlpaslan KABAN
Alpaslan KABAN
STSamet Topuz
Samet Topuz
PSPınar Saip
Pınar Saip
HSHamdullah Sözen
Hamdullah Sözen
YSYavuz Salihoğlu
Yavuz Salihoğlu

1 February 2019 in Journal of Obstetrics and Gynaecology Canada
Verified
Journal Article
Closed access
AKAlpaslan KABAN
Alpaslan KABAN
STSamet Topuz
Samet Topuz
HSHamdullah Sozen
Hamdullah Sozen
YSYavuz Salihoglu
Yavuz Salihoglu